$HRTX 8-K SEC Filings

Filed On	Filing
29 Sep 2026	8-K: Entry into a Material Definitive Agreement On September 23, 2026 (the “Effective Date”), Heron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a multi-product Development and License Agreement (the “License Agreement”) with Long Grove Pharmaceuticals, LLC...
14 Aug 2026	8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders
10 Aug 2026	8-K: Results of Operations and Financial Condition
25 Jun 2026	8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
16 Jun 2026	8-K: Submission of Matters to a Vote of Security Holders
02 Jun 2026	8-K: Other Events
11 May 2026	8-K: Results of Operations and Financial Condition
06 Apr 2026	8-K: Departure/Election of Directors or Officers; Compensation
26 Feb 2026	8-K: Results of Operations and Financial Condition
09 Jan 2026	8-K: Regulation FD Disclosure
04 Nov 2025	8-K: Results of Operations and Financial Condition
29 Oct 2025	8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
15 Oct 2025	8-K: Submission of Matters to a Vote of Security Holders
28 Aug 2025	8-K: Entry into a Material Definitive Agreement
15 Aug 2025	8-K: Entry into a Material Definitive Agreement; Material Modification to Rights of Security Holders +2 more
12 Aug 2025	8-K: Entry into a Material Definitive Agreement; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
12 Aug 2025	8-K: Entry into a Material Definitive Agreement
08 Aug 2025	8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more
18 Jun 2025	8-K: Submission of Matters to a Vote of Security Holders
06 May 2025	8-K: Results of Operations and Financial Condition

Comments